Sue Perera

Sue Perera

Auto-generated profile, based on publicly available information

Sue Perera

Moderna, Inc., Cambridge, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2026 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
NLNicola Longo
Nicola Longo
Barbara K. BurtonBarbara K. Burton
Barbara K. Burton
SVShailja Vaghela
Shailja Vaghela
FMFan Mu
Fan Mu
AWAolin Wang
Aolin Wang
SPSue Perera
Sue Perera
Phenylketonuria (PKU) is caused by defective catabolism of phenylalanine (Phe), resulting in Phe accumulation and subsequent neurocognitive impairment. This retrospective study used a large United States claims database linked to laboratory records (6/2018–05/2023) to compare comorbidities, healthcare resource utilization, and healthcare costs between individuals with PKU and matched controls, stratified by age and Phe level, as well as describe pharmacological treatment patterns among individuals with PKU. The study included 5729 and 2648 matched pairs aged ≥ 12 and < 12 years, respectively (mean age: 31 and 3 years; 60% and 47% female). Individuals aged ≥ 12 years with PKU had significantly higher prevalence of neuropsychiatric and cognitive comorbidities than controls, including intellectual or developmental disabilities (prevalence difference: 5.2%), fatigue and malaise (4.9%), and anxiety (4.2%; all p < 0.05), along with other comorbidities across multiple organ systems. Individuals aged ≥ 12 years with PKU also accessed the healthcare system more than controls (39% more hospitalizations, 18% more emergency room visits, and 25% more outpatient visits) and incurred higher medical and pharmacy costs ($2869 and $9075, respectively; p < 0.05). Individuals aged < 12 years similarly had higher burden than controls, but only for certain outcomes and at smaller magnitudes. Individuals with Phe ≥ 600 μmol/L showed a greater incremental burden for certain comorbidities, such as intellectual or developmental disabilities, compared to individuals with Phe < 600 μmol/L. These findings demonstrate the substantial burden of PKU across age and Phe level strata, notably in those aged ≥ 12 years, highlighting the need for improved treatments.

9 March 2026 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
BSBernd C. Schwahn
Bernd C. Schwahn
GBGerard T. Berry
Gerard T. Berry
HVHilary J. Vernon
Hilary J. Vernon
HLHong Li
Hong Li
JIJ. Lawrence Merritt Ii
J. Lawrence Merritt Ii
VSVanja Sikirica
Vanja Sikirica
Background: Propionic acidemia (PA) is a rare disease resulting in toxic accumulation of metabolites that cause metabolic decompensation events (MDEs). Natural history characterization of PA is limited partly due to its rarity and complexity. This study examined clinical events in participants with PA and their correlation with biomarkers to better understand the disease. Methods: Participants diagnosed with PA (early- versus late-onset) were evaluated every 6 months from baseline to month 36. Outcome measures included annualized MDEs and changes in 3-hydroxypropionic acid (3-HP), 2-methylcitrate (2-MC), and propionylcarnitine (C3) concentrations. Blood samples were collected at each visit and during MDEs for plasma biomarker analyses. Relative risk (RR) was calculated based on MDE rates and biomarker levels. Results: Most participants (n/ N = 49/50, 98.0%) reported MDEs. Annualized MDE rates were highest in participants aged 0 to ≤ 1 and > 1 to ≤ 2 versus > 12 to ≤ 18 years (2.6 and 2.4, respectively, vs 0.2) and for early-onset versus late-onset PA (1.2 vs 0.3). A 50% decrease in plasma biomarkers was associated with a statistically significant reduction in RR of MDEs for 3-HP (RR: 0.7, 95% CI: 0.6–0.9; p < 0.01) and a substantial reduction for C3 (RR: 0.6, 95% CI: 0.4–0.9; p = 0.017); no effect was observed for 2-MC. Conclusions: MDE rates were higher in the youngest participants (0 to ≤ 2 years) versus participants aged > 12 years, and with early- versus late-onset PA. Lower concentrations of 3-HP and C3 were associated with a reduced MDE risk. These findings may guide biomarker or clinical endpoints in future treatment trials.

9 May 2025 in Clinical Drug Investigation
Verified
Journal Article
Open access
PDF file
SPSue Perera
Sue Perera
GBGeetanjoli Banerjee
Geetanjoli Banerjee
VSVanja Sikirica
Vanja Sikirica
EKEliza Kruger
Eliza Kruger
ECEmily Combe
Emily Combe
SYSufin Yap
Sufin Yap
An early cost-utility model by Bretos-Azcona et al., assessing the cost-effectiveness of mRNA-based therapy in methylmalonic and propionic acidemia (MMA and PA) in the UK, was recently published in Clinical Drug Investigation [1]. We commend the authors for their thoughtful work but offer our comments on the assumptions and model inputs included within the publication. In early modelling, particularly in rare diseases where data are scarce, every effort should be made to source inputs from the most robust sources and validate key concepts with experts. Clear justifications for some data and assumptions were lacking, and alternative inputs may be more suitable.

10 October 2026 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
JHJudit Hagymásy
Judit Hagymásy
TZTamás Zelei
Tamás Zelei
SVShailja Vaghela
Shailja Vaghela
DMDóra Mezei
Dóra Mezei
HVHédi Varga
Hédi Varga
SPSue Perera
Sue Perera
Background/Objectives Phenylketonuria (PKU) is a rare autosomal recessive metabolic disorder resulting from a deficiency in phenylalanine hydroxylase (PAH) enzyme activity. This systematic literature review (SLR) aims to synthesize the available evidence on the economic and humanistic burden of PKU on patients and their caregivers. Methods A comprehensive SLR was conducted using PubMed, Embase, Cochrane Library, International Prospective Register of Systematic Reviews (PROSPERO), EconLit, and the Cost-Effectiveness Analysis (CEA) Registry, from database inception to June 2026. Eligible studies were published in English, included individuals diagnosed with PAH deficiency (including PKU) and/or their caregivers, and reported original data on either the economic or humanistic burden of the condition. Results Of 2131 records identified, 1330 were screened after deduplication, and 313 underwent full-text review. A total of 130 studies were included, with 44 reporting on economic burden and 87 covering humanistic burden-related outcomes. The economic burden of dietary management was substantial, with mean per patient per year (PPPY) costs ranging from US$1634 to US$35,946, and an estimated 233–359 h PPPY dedicated to diet-related activities. Humanistic burden was also significant; the long-term metabolic control significantly influenced multiple domains of health-related quality of life (HRQoL). In a study involving adults with PKU (n = 88), dietary protein restriction was found to be negatively associated with HRQoL (Rp = 0.265, p < 0.05), and similarly, anxiety was also negatively correlated with blood phenylalanine (Phe) levels (Rs = 0.186–0.209, p < 0.05). Conclusions Findings underscore the substantial financial, time, and psychological burden of PKU, particularly in relation to dietary management.